

# Resolution

of the Federal Joint Committee on an Amendment of the  
Pharmaceuticals Directive (AM-RL):  
Annex XII – Benefit Assessment of Medicinal Products with  
New Active Ingredients according to Section 35a SGB V  
Pirtobrutinib (relapsed or refractory mantle cell lymphoma);  
restriction of the authority to supply care

From 4 June 2026

At their session on 4 June 2026, the Federal Joint Committee (G-BA) resolved to amend the Pharmaceuticals Directive (AM-RL) in the version dated 18 December 2008/ 22 January 2009 (Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended by the publication of the resolution of D Month YYYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

- I. **In Annex XII, the following information shall be added after No. 5 to the information on the benefit assessment of Pirtobrutinib in accordance with the resolution of 4 June 2026:**

## **Pirtobrutinib**

Resolution of: 4 June 2026

Entry into force on: 4 June 2026

Federal Gazette, BAnz AT DD. MM YYYY Bx

### **Restriction of the authority to supply care according to Section 35a, paragraph 3b, sentence 2 SGB V**

For the active ingredient pirtobrutinib in the treatment of:

"Adults with relapsed or refractory mantle cell lymphoma who have been pretreated with a Bruton's tyrosine kinase inhibitor",

the authority to supply care according to Section 35a, paragraph 3b, sentence 2 SGB V is limited to those care providers who participate in the required routine practice data collection.

Care providers within the meaning of this resolution are physicians participating in SHI-accredited medical care, medical care centres and facilities according to Section 95 SGB V as well as hospitals approved for care provision according to Section 108 SGB V.

Care providers who are not authorised to supply the medicinal product may exceptionally prescribe the medicinal product at the expense of the statutory health insurance, provided that the prescription is made exclusively for the purpose of further prescribing the medicinal product and ensuring the success of the therapy after prior consultation with the care provider authorised to supply care and the same continues to be responsible for data collection, thus not jeopardising the purpose of the restriction of the authority to supply care, namely to obtain valid data from the supply of medicinal products to insured persons.

Participation in the required routine practice data collection is ensured by the proper (proven in writing) participation of the (approved) healthcare provider in the data collection for the required routine practice data collection on the basis of the confirmed study protocol of the pharmaceutical company.

The coordination of the unauthorised care provider with the authorised care provider should be documented in the patient record of the unauthorised care provider.

## **II. Entry into force**

The resolution will enter into force on the day of its publication on the internet on the G-BA website on 4 June 2026.

The restriction of the authority to supply care to those care providers who participate in the required routine practice data collection, as regulated in the resolution, only takes effect with the start of the routine practice data collection, which is determined in a separate resolution.

The justification for this resolution will be published on the G-BA website at [www.g-ba.de](http://www.g-ba.de).

Berlin, 4 June 2026

Federal Joint Committee  
in accordance with Section 91 SGB V  
The Chair

Prof. Hecken